With low or very low certainty evidence relative to OX alone, Aidi Injection (CA724: MD -14.19, 95% CI -21.54 to −6.84, I2 = 97%; CEA: MD -6.15, 95% CI -9.34 to −2.96, I2 = 95%), Compound Kushen Injection (CA724: MD -12.52, 95% CI -17.92 to −7.11, I2 = 71%; CEA: MD -7.54, 95% CI -10.05 to −5.03, I2 = 95%; CA125: MD -3.76, 95%CI -6.12 to −1.41, I2 = 11%), and Compound Mylabris preparations (CA724: MD -24.90, 95% CI -36.79 to −13.02, I2 = NA; CEA: MD -5.68, 95% CI -9.53 to −1.83, I2 = 79%) might be the most effective CCPPs for reduction of tumor markers (Figure 3 and Supplementary Appendix S9). This evidence concerns the gene CEACAM5 and neoplasm.